📣 VC round data is live. Check it out!

TriSalus Life Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for TriSalus Life Sciences and similar public comparables like RxSight, Ilex Medical, Asterasys, Medinice and more.

TriSalus Life Sciences Overview

About TriSalus Life Sciences

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.


Founded

2020

HQ

United States

Employees

110

Financials (LTM)

Revenue: $49M
EBITDA: ($15M)

EV

$183M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

TriSalus Life Sciences Financials

TriSalus Life Sciences reported last 12-month revenue of $49M and negative EBITDA of ($15M).

In the same LTM period, TriSalus Life Sciences generated $41M in gross profit, ($15M) in EBITDA losses, and had net loss of ($30M).

Revenue (LTM)


TriSalus Life Sciences P&L

In the most recent fiscal year, TriSalus Life Sciences reported revenue of $45M and EBITDA of ($17M).

TriSalus Life Sciences is unprofitable as of last fiscal year, with gross margin of 85%, EBITDA margin of (37%), and net margin of (87%).

See analyst estimates for TriSalus Life Sciences
LTMLast FY202320242025202620272028
Revenue$49M$45M$19M$29M$45M
Gross Profit$41M$38M$16M$25M$38M
Gross Margin85%85%86%86%85%
EBITDA($15M)($17M)($58M)($26M)($33M)
EBITDA Margin(31%)(37%)(315%)(89%)(73%)
EBIT Margin(50%)(58%)(293%)(123%)(60%)
Net Profit($30M)($39M)($59M)($30M)($39M)
Net Margin(62%)(87%)(319%)(102%)(87%)
Net Debt-$13M---

Financial data powered by Morningstar, Inc.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences has current market cap of $205M, and enterprise value of $183M.

Market Cap Evolution


TriSalus Life Sciences' stock price is $3.33.

TriSalus Life Sciences share price decreased by 2.5% in the last 30 days, and by 38.8% in the last year.

TriSalus Life Sciences has an EPS (earnings per share) of $-0.64.

See more trading valuation data for TriSalus Life Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$183M$205M-9.3%-2.5%-16.5%-38.8%$-0.64

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

TriSalus Life Sciences Valuation Multiples

TriSalus Life Sciences trades at 3.7x EV/Revenue multiple, and (12.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for TriSalus Life Sciences

EV / Revenue (LTM)


TriSalus Life Sciences Financial Valuation Multiples

As of June 3, 2026, TriSalus Life Sciences has market cap of $205M and EV of $183M.

TriSalus Life Sciences has a P/E ratio of (6.7x).

LTMLast FY202320242025202620272028
EV/Revenue3.7x4.0x9.9x6.2x4.0x
EV/EBITDA(12.2x)(11.1x)(3.1x)(7.0x)(5.5x)
EV/EBIT(7.4x)(7.0x)(3.4x)(5.1x)(6.8x)
EV/Gross Profit4.4x4.8x11.5x7.2x4.8x
P/E(6.7x)(5.2x)(3.5x)(6.8x)(5.2x)
EV/FCF-(9.7x)(3.6x)(4.4x)(9.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified TriSalus Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

TriSalus Life Sciences Margins & Growth Rates

TriSalus Life Sciences grew revenue by 19% but EBITDA decreased by 22% in the last fiscal year.

In the most recent fiscal year, TriSalus Life Sciences reported gross margin of 85%, EBITDA margin of (37%), and net margin of (87%).

See estimated margins and future growth rates for TriSalus Life Sciences

TriSalus Life Sciences Margins

Last FY202420252026202720282029
Gross Margin85%86%85%86%
EBITDA Margin(37%)(89%)(73%)(24%)
EBIT Margin(58%)(123%)(60%)(42%)
Net Margin(87%)(102%)(87%)(34%)
FCF Margin(42%)(140%)(42%)-

TriSalus Life Sciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth19%59%53%19%
Gross Profit Growth20%59%51%20%
EBITDA Growth(22%)(55%)26%(61%)
EBIT Growth(14%)(33%)(25%)(16%)
Net Profit Growth(53%)(49%)31%(53%)
FCF Growth-(20%)(54%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

TriSalus Life Sciences Operational KPIs

TriSalus Life Sciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.

TriSalus Life Sciences' Rule of 40 is (5%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TriSalus Life Sciences' Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for TriSalus Life Sciences
LTMLast FY202320242025202620272028
Rule of 401%(5%)---
Bessemer Rule of X48%23%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.6M---
S&M Expenses to Revenue66%64%92%88%64%
G&A Expenses to Revenue41%48%127%61%48%
R&D Expenses to Revenue29%33%159%60%33%
Opex to Revenue-144%378%209%144%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

TriSalus Life Sciences Competitors

TriSalus Life Sciences competitors include RxSight, Ilex Medical, Asterasys, Medinice, Lucid Diagnostics, Pro-Dex, Huons Co, Utah Medical, Sanara MedTech and Anika Therapeutics.

Most TriSalus Life Sciences public comparables operate across Medical Devices, DeepTech, HealthTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
RxSight(0.0x)(0.0x)0.1x0.0x
Ilex Medical0.4x-3.3x-
Asterasys7.5x6.3x22.7x18.2x
Medinice--(111.9x)-
Lucid Diagnostics44.1x35.6x(3.7x)(4.0x)
Pro-Dex3.3x2.9x15.7x-
Huons Co0.7x-5.2x-
Utah Medical3.3x-8.8x-

This data is available for Pro users. Sign up to see all TriSalus Life Sciences competitors and their valuation data.

Start Free Trial

TriSalus Life Sciences VC Funding History

Before going public, TriSalus Life Sciences raised $70M in total equity funding, across 4 rounds.


TriSalus Life Sciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-22Series E-$24M-TriSalus Life Sciences raised $81.4 million in a funding round closed on November 10, 2022. The company reported $45.2 million in full-year 2025 revenue, representing 53% growth compared to the prior year, with $13.2 million reported in the fourth quarter 2025.
Mar-17Series DORI Capital; Partisan Management Group$13M--
Dec-15Series CHigh Country Venture; KMG Capital Partners; MCG Capital; Partisan Management Group; Tullis Health Investors$15M--
Nov-13Series BHigh Country Venture; MCG Capital; Partisan Management Group$18M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About TriSalus Life Sciences

When was TriSalus Life Sciences founded?TriSalus Life Sciences was founded in 2020.
Where is TriSalus Life Sciences headquartered?TriSalus Life Sciences is headquartered in United States.
How many employees does TriSalus Life Sciences have?As of today, TriSalus Life Sciences has over 110 employees.
Who is the CEO of TriSalus Life Sciences?TriSalus Life Sciences' CEO is Mary T. Szela.
Is TriSalus Life Sciences publicly listed?Yes, TriSalus Life Sciences is a public company listed on Nasdaq.
What is the stock symbol of TriSalus Life Sciences?TriSalus Life Sciences trades under TLSI ticker.
When did TriSalus Life Sciences go public?TriSalus Life Sciences went public in 2023.
Who are competitors of TriSalus Life Sciences?TriSalus Life Sciences main competitors include RxSight, Ilex Medical, Asterasys, Medinice, Lucid Diagnostics, Pro-Dex, Huons Co, Utah Medical, Sanara MedTech, Anika Therapeutics.
What is the current market cap of TriSalus Life Sciences?TriSalus Life Sciences' current market cap is $205M.
What is the current revenue of TriSalus Life Sciences?TriSalus Life Sciences' last 12 months revenue is $49M.
What is the current revenue growth of TriSalus Life Sciences?TriSalus Life Sciences revenue growth (NTM/LTM) is 32%.
What is the current EV/Revenue multiple of TriSalus Life Sciences?Current revenue multiple of TriSalus Life Sciences is 3.7x.
Is TriSalus Life Sciences profitable?No, TriSalus Life Sciences is not profitable.
What is the current EBITDA of TriSalus Life Sciences?TriSalus Life Sciences has negative EBITDA and is not profitable.
What is TriSalus Life Sciences' EBITDA margin?TriSalus Life Sciences' last 12 months EBITDA margin is (31%).
What is the current EV/EBITDA multiple of TriSalus Life Sciences?Current EBITDA multiple of TriSalus Life Sciences is (12.2x).
How many companies TriSalus Life Sciences has acquired to date?TriSalus Life Sciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies TriSalus Life Sciences has invested to date?TriSalus Life Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to TriSalus Life Sciences

Lists including TriSalus Life Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial